Skip to Main Content

Paper Details

Exposure-response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy.
Br J Clin Pharmacol
2
2022
Author NameAffiliation
Ronald de WitErasmus MC Cancer Institute
Michiel S van der HeijdenNetherlands Cancer Institute-Antoni van Leeuwenhoek Hospital
Cora N SternbergEnglander Institute for Precision Medicine, Sandra and Edward Meyer Cancer Center
Alexandra DrakakiUniversity of California Los Angeles
Evan Y YuUniversity of Washington and Fred Hutchinson Cancer Center
  • 1 - 5

Datasets

Release 1.2